Avantax Advisory Services Inc. Sells 1,252 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Avantax Advisory Services Inc. trimmed its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 13.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,827 shares of the medical equipment provider’s stock after selling 1,252 shares during the quarter. Avantax Advisory Services Inc.’s holdings in BioLife Solutions were worth $203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of BLFS. State Street Corp grew its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares in the last quarter. Geode Capital Management LLC increased its position in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares during the period. Barclays PLC lifted its position in BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after purchasing an additional 5,638 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new stake in BioLife Solutions during the 3rd quarter valued at about $1,018,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BLFS. HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. StockNews.com upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Finally, KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Stock Up 2.6 %

BioLife Solutions stock opened at $26.17 on Friday. The business’s 50-day simple moving average is $26.35 and its two-hundred day simple moving average is $25.52. The company has a market cap of $1.23 billion, a PE ratio of -24.69 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period in the previous year, the business posted ($0.21) EPS. Equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarah Aebersold sold 1,091 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00. Following the completion of the sale, the insider now owns 58,816 shares in the company, valued at approximately $1,470,400. This trade represents a 1.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,117 shares of company stock valued at $534,442 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.